Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has paid milestone payment under its collaboration with Morphosys, related to the IND filing in December 2010 and commencement of a Phase 1 clinical trial of a HuCAL-derived, fully human antibody in the therapeutic area of oncology.
Subscribe to our email newsletter
Earlier, Pfizer and Morphosys tied up in December 2003 to develop therapeutic antibodies.
Both the parties further extended their collaboration in 2006 under which Pfizer secured an option to begin several therapeutic antibody projects with MorphoSys.
MorphoSys chief scientific officer Marlies Sproll said they are delighted to add Pfizer to the list of partner companies running clinical trials with HuCAL-based antibodies.
"In total, seven different partners from the pharmaceutical and biotechnology industry are currently running clinical trials with our antibodies," Sproll said.